Medical Use of Cannabis Poses Risks in Adolescents – Medscape

✦ New
CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
⚒ Cannabis News  |  CED Clinic
Adolescent MedicineNeurodevelopmentCbdThcPediatrics
Why This Matters

Adolescent brain development continues through age 25, making this population uniquely vulnerable to cannabis effects on cognition, executive function, and psychiatric outcomes. Clinicians treating adolescents with cannabis need specific risk-benefit frameworks that account for developmental neurobiology, not just adult safety profiles.

Clinical Summary

Adolescent cannabis use, including medical use, carries distinct neurodevelopmental risks due to ongoing brain maturation through the mid-twenties. The adolescent endocannabinoid system is still developing, making it more susceptible to disruption from exogenous cannabinoids. Evidence suggests particular vulnerability in areas of executive function, memory consolidation, and emotional regulation. Medical cannabis in this population requires careful consideration of formulation, dosing, duration, and indication severity relative to potential long-term cognitive and psychiatric impacts.

Dr. Caplan’s Take

“I approach adolescent medical cannabis with extreme caution โ€” the bar for medical necessity must be considerably higher than in adults. When we do prescribe, I favor CBD-dominant formulations with the lowest effective THC content and built-in reassessment timelines.”

Clinical Perspective
🧠 Clinicians should establish clear protocols for adolescent cannabis medicine including comprehensive baseline cognitive and psychiatric assessment, preference for non-psychoactive cannabinoids when clinically appropriate, and regular developmental monitoring. Consider whether conventional therapies have been adequately trialed and involve pediatric subspecialists when available.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

FAQ

What is the clinical relevance rating of this cannabis research?

This study has been assigned CED Clinical Relevance #76 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that warrant close monitoring by healthcare professionals.

What age group does this cannabis research focus on?

The research focuses on adolescent medicine, examining cannabis effects in young people. This demographic is particularly important due to ongoing brain development during the teenage years.

What aspects of brain development are being studied in relation to cannabis use?

The study examines neurodevelopmental effects of cannabis use in adolescents. This research is crucial because the adolescent brain continues developing until the mid-twenties, making it potentially vulnerable to cannabis exposure.

Which cannabis compounds are being investigated in this research?

The study focuses on both CBD (cannabidiol) and THC (tetrahydrocannabinol), the two primary active compounds in cannabis. These compounds have different effects on the brain and may impact adolescent neurodevelopment differently.

Why is this cannabis research particularly important for clinicians?

This research provides emerging evidence about cannabis effects on developing brains, which is essential for clinical decision-making. As cannabis legalization expands, healthcare providers need current data to counsel adolescent patients and families appropriately.